BeiGene, Ltd. (ONC)vsPHAXIAM Therapeutics S.A. (PHXM)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
PHXM
PHAXIAM Therapeutics S.A.
$3.10
0.00%
HEALTHCARE · Cap: $28.90M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 89368% more annual revenue ($5.34B vs $5.97M). ONC leads profitability with a 5.4% profit margin vs -1.9%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
PHXM
Avoid11
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for PHXM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -38.6% — below average capital efficiency
Revenue declined 66.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : PHXM
The strongest argument for PHXM centers on Price/Book.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : PHXM
The primary concerns for PHXM are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while PHXM is a turnaround play — different risk/reward profiles.
PHXM carries more volatility with a beta of 1.96 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 11/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →PHAXIAM Therapeutics S.A.
HEALTHCARE · BIOTECHNOLOGY · USA
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. The company is headquartered in Lyon, France.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?